| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3256 |
| Trial ID | NCT05633615 |
| Disease | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel |
| Co-treatment | mosunetuzumab/polatuzumab |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | SWOG Cancer Research Network |
| Other ID(s) | S2114|NCI-2022-07930|S2114|S2114|U10CA180888 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||